|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||
| Transforming Growth Factor-beta (TGF-β) is a pleiotropic cytokine which exists in five isoforms, known as TGF-β1-5, with homologies of 70-80% and no homology to TGF-α. TGF-β1 is the most abundant form in lymphoid organs and is found almost ubiquitously while other isoforms are expressed in a more restricted distribution. The biologically active forms of all isoforms are disulfide-linked homodimers. The heat- and acid- stable monomeric subunits have a length of 112 amino acids. The isoforms of TGF-β arise by proteolytic cleavage of longer precursors; the isoforms are derived from the carboxyterminal ends of these precursors. Isoforms isolated from different species are evolutionarily closely conserved and have sequence identities on the order of 98%. Mature human, porcine, simian, chicken and bovine TGF-β1 are identical and differ from mouse TGF-β1 in a single amino acid.
TGF-β1 is produced in very high levels by platelets. Other cellular sources of TGF-β1 include macrophages, lymphocytes, endothelial cells, chondrocytes, and leukemic cells. TGF-β1 secretion can be induced by steroids, retinoids, EGF, NGF, vitamin D3, and IL-1. Activities of TGF-β1 include inhibition of cell growth for inhibitor for normal and transformed epithelial cells, endothelial cells, fibroblasts, neurons, and lymphoid cells and other hematopoietic cell types. TGF-β1 inhibits the proliferation of T cells and NK cells and downregulates the activities of activated macrophages. TGF-β1 blocks the anti-tumor activity of IL-2 – bearing lymphokine-activated killer (LAK) cells. Recently, TGF-β1 has been found to have a critical role in the development of regulatory T cells. Dendritic cells exposed to tumors have been reported to secrete TGF-β1 and stimulate expansion of naturally-occurring T reg cells. Moreover, TGF-β1 has been shown to act as a costimulatory factor for expression of Foxp3, leading to the differentiation of CD4+CD25+ Treg cells from peripheral CD4+CD25- progeny. TGF-β-induced regulatory T cells have been termed Ti-Treg. This Human/Mouse TGF-β1 ELISA Ready-SET-Go! Kit (with Pre-Coated Plates) contains the necessary reagents, standards, buffers and diluents for performing quantitative enzyme-linked immunosorbent assays (ELISA). This ELISA set is specifically engineered for accurate and precise measurement of mouse or human TGF-β1 protein levels from samples including serum, plasma, and supernatants from cell cultures. Note: This sandwich ELISA recognizes the mature/active form of TGF-β1. Samples (but not standards) should be acid-treated and then neutralized to activate the latent TGF-β1 to the immunoreactive form. Samples should be tested in the ELISA immediately after acid treatment and neutralization. See 'Experimental Procedure'. | ||||||||||||||||||||||||
| Components | ||||||||||||||||||||||||
| Pre-coated ELISA Plate Detection Antibody. Pre-titrated, biotin-conjugated antibody Standard. Recombinant cytokine for generating standard curve and calibrating samples Assay Diluent. 5X concentrated ELISA Wash Buffer Powder. Reconstitute in 1 L dI water Detection enzyme. Pre-titrated Avidin-HRP Substrate Solution. Tetramethylbenzidine (TMB) Substrate Solution Stop Solution. 5 mls of 1X solution per plate Certificate of Analysis. Lot-specific instructions for dilution of antibodies and standards | ||||||||||||||||||||||||
| Applications Reported | ||||||||||||||||||||||||
| For research use only, not for diagnostic or therapeutic use. | ||||||||||||||||||||||||
| References | ||||||||||||||||||||||||
| Miyazono, K., et al. 1992. Structure, function and possible clinical application of transforming growth factor-beta. J Dermatol. 19: 644-647. Roberts, A., et al. 1993. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 8: 1-9. Peng, Y., et al. 2004. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. PNAS. 101: 4572-4577. Fantini, M., et al. 2005. TGF-beta – induced Foxp3+ regulatory T cells suppress Th1-mediated experimental colitis. Gut. [Epub ahead of print] Zheng, S.G., et al. 2002. Generation ex vivo of TGF-b-producing regulatory T cells from CD4+CD25- precursors. J. Immunol. 169: 4183-4189. | ||||||||||||||||||||||||
| Protocol | ||||||||||||||||||||||||
| To view protocol, please download the TDS by clicking the PDF button above. | ||||||||||||||||||||||||
| Home | Index | Site Map | FAQ | Terms & Conditions | Distributors | Careers | Contact Us |
|
Copyright © 2000-2010 eBioscience, Inc. Unless indicated otherwise, all products are For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for further distribution without written consent. Not all products available in all regions. |